DRUG: SURFACTANT (PORCINE) – PORACTANT ALFA (CUROSURF)

PRESENTATION: Vials: 120 mg / 1.5 mL  
                              240 mg / 3 mL

ACTION & INDICATION: Pulmonary surfactant derived from pigs and used for the prevention or treatment of respiratory distress syndrome, according to NCCU guidelines.

DOSE: Rescue treatment
      Initial dose: 2.5mL/kg (200mg/kg)
      Subsequent doses: 1.25mL/kg (100mg/kg). Up to 2 subsequent doses at 12 hourly intervals may be administered. Maximum total dose: 400mg/kg

Prophylaxis
Initial dose: 1.25mL-2.5mL/kg 100mg – 200mg/kg) administered within 15 minutes of birth.

Subsequent doses of 1.25mL (100mg) /kg may be given 6-12 hours after the first dose and then 12 hours later in babies who remain ventilator dependent. Maximum total dose: 300-400mg/kg

ADMINISTRATION: For intratracheal administration only.
Poractant is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Poractant should NOT be instilled into a main stem bronchus.

Administer as outlined in the NCCU “Surfactant Replacement Therapy Guidelines”.

ADVERSE EFFECTS: Adverse effects associated with dosing procedure: Transient bradycardia, oxygen desaturation, ETT reflux, pallor, vasoconstriction, hypotension, ETT blockage, hypertension, hypocarbia, hypercarbia, apnoea.

COMMENTS: Warm vial to room temperature before use. Do not use artificial warming methods. Do not shake.

Store open and unopened vials at 2 - 8°C.
Discard 12 hours after opening.
Evaluate clinical condition before and for 30 minutes after each dose

REFERENCES: Neofax 2013

DATE: October 2013